Immunocore Holdings plc is a biotechnology business based in the US. Immunocore shares (IMCR) are listed on the NASDAQ and all prices are listed in US Dollars. Immunocore employs 291 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Immunocore
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IMCR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Immunocore stock price (NASDAQ: IMCR)Use our graph to track the performance of IMCR stocks over time.
Immunocore shares at a glance
|Latest market close||$41.00|
|52-week range||$26.00 - $61.99|
|50-day moving average||$37.45|
|200-day moving average||$40.20|
|Wall St. target price||$51.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy Immunocore shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Immunocore stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Immunocore price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||4.09%|
|3 months (2021-04-30)||1.59%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
|Revenue TTM||$30.1 million|
|Gross profit TTM||$30.1 million|
|Return on assets TTM||-22.77%|
|Return on equity TTM||-64.85%|
|Market capitalisation||$1.4 billion|
TTM: trailing 12 months
Shorting Immunocore shares
There are currently 259,765 Immunocore shares held short by investors – that's known as Immunocore's "short interest". This figure is 22% up from 212,985 last month.
There are a few different ways that this level of interest in shorting Immunocore shares can be evaluated.
Immunocore's "short interest ratio" (SIR)
Immunocore's "short interest ratio" (SIR) is the quantity of Immunocore shares currently shorted divided by the average quantity of Immunocore shares traded daily (recently around 55034.957627119). Immunocore's SIR currently stands at 4.72. In other words for every 100,000 Immunocore shares traded daily on the market, roughly 4720 shares are currently held short.
To gain some more context, you can compare Immunocore's short interest ratio against those of similar companies.
However Immunocore's short interest can also be evaluated against the total number of Immunocore shares, or, against the total number of tradable Immunocore shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immunocore's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Immunocore shares in existence, roughly 10 shares are currently held short) or 0.012% of the tradable shares (for every 100,000 tradable Immunocore shares, roughly 12 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immunocore.
Find out more about how you can short Immunocore stock.
Immunocore share dividends
We're not expecting Immunocore to pay a dividend over the next 12 months.
Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom. .
Stocks similar to Immunocore
Immunocore in the news
Is Immunocore Holdings plc (IMCR) A Good Stock To Buy?
Tracking Baker Brothers Portfolio - Q1 2021 Update
Frequently asked questionsWhat percentage of Immunocore is owned by institutions?
Currently 34.926% of Immunocore shares are held by institutions. How many people work for Immunocore?
Latest data suggests 291 work at Immunocore. When does the fiscal year end for Immunocore?
Immunocore's fiscal year ends in December. Where is Immunocore based?
Immunocore's address is: 92 Park Drive, Abingdon, United Kingdom, OX14 4RY
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert